<bill session="116" type="s" number="366" updated="2022-11-01T15:32:52Z">
  <state datetime="2019-02-06">REFERRED</state>
  <status>
    <introduced datetime="2019-02-06"/>
  </status>
  <introduced datetime="2019-02-06"/>
  <titles>
    <title type="display">FLAT Prices Act</title>
    <title type="short" as="introduced">FLAT Prices Act</title>
    <title type="short" as="introduced">Forcing Limits on Abusive and Tumultuous Prices</title>
    <title type="official" as="introduced">A bill to shorten monopoly periods for prescription drugs that are the subjects of sudden price hikes.</title>
  </titles>
  <sponsor bioguide_id="D000563"/>
  <cosponsors>
    <cosponsor bioguide_id="B001277" joined="2019-02-06"/>
    <cosponsor bioguide_id="B000944" joined="2019-02-07"/>
    <cosponsor bioguide_id="H001075" joined="2019-02-06"/>
    <cosponsor bioguide_id="K000367" joined="2019-02-06"/>
    <cosponsor bioguide_id="P000595" joined="2019-09-25"/>
    <cosponsor bioguide_id="S001203" joined="2019-02-06"/>
  </cosponsors>
  <actions>
    <action datetime="2019-02-06">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2019-02-06" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
      <reference ref="CR S921-922" label="text"/>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="h" number="1188" relation="identical"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Business records"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Government information and archives"/>
    <term name="Health care costs and insurance"/>
    <term name="Inflation and prices"/>
    <term name="Licensing and registrations"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2021-09-10T18:33:22Z" status="Introduced in Senate">Forcing Limits on Abusive and Tumultuous Prices or the FLAT Prices Act

This bill directs the Food and Drug Administration to reduce the market exclusivity of an approved prescription drug if the drug manufacturer increases the drug's price by more than a specified percentage. This reduction may be waived under specified circumstances.</summary>
</bill>
